{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-066645","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.401569+00:00","generated_at":"2026-06-01T07:30:03.752138+00:00","sec_items":["1.01","3.02","3.03","5.03","5.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inhibrx Biosciences completes spin-off from RemainCo, lists 14.5M shares outstanding","bullets":["Completed spin-off on May 29, 2024; 92% of Inhibrx Biosciences shares distributed to RemainCo shareholders at 1:4 ratio.","As of May 30, 2024, 14,475,904 shares of common stock outstanding post-distribution.","Issued warrants for up to 991,849 shares at $0.0001 exercise price, no expiration; also issued 1,838 shares to Oxford Finance.","Entered registration rights agreement requiring filing of resale registration statement within 10 business days.","Entered employment agreements with CEO Lappe ($695,250 base), CFO Eckelman ($535,600), and CAO Deck ($460,100) with 12-month severance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-066645","json":"https://secwatch.observer/filing/0001104659-24-066645.json","markdown":"https://secwatch.observer/filing/0001104659-24-066645.md","text":"https://secwatch.observer/filing/0001104659-24-066645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/0001104659-24-066645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:30:03.752138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"216fe0ca09c824bba6aa4512c5a9f1ec7f77fb21","claim":"Inhibrx Biosciences, Inc. underwent a change of control involving Inhibrx, Inc. (closed 2024-05-29).","evidence_excerpt":"On May 29, 2024, Inhibrx, Inc., a Delaware corporation (“RemainCo”), completed the distribution of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc., a Delaware corporation (the “Company”), to holders of shares of RemainCo’s common stock as of the distribution record date of May 17, 2024, on a pro rata basis (the “Distribution”), at a ratio of one share of the Company’s common stock for every four shares of RemainCo’s issued and outstanding common stock held on the distribution record date.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/0001104659-24-066645-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Inhibrx, Inc."},{"label":"Closing","value":"2024-05-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}